EA201201219A1 - PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS) - Google Patents

PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)

Info

Publication number
EA201201219A1
EA201201219A1 EA201201219A EA201201219A EA201201219A1 EA 201201219 A1 EA201201219 A1 EA 201201219A1 EA 201201219 A EA201201219 A EA 201201219A EA 201201219 A EA201201219 A EA 201201219A EA 201201219 A1 EA201201219 A1 EA 201201219A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
metabolic
retinoprotective
options
path
Prior art date
Application number
EA201201219A
Other languages
Russian (ru)
Other versions
EA020389B1 (en
Inventor
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Олег Олегович ТИХОНЕНКО
Original Assignee
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анастасия Геннадьевна ЧЕЛЯЕВА, Владимир Павлович ЛОБКО filed Critical Анастасия Геннадьевна ЧЕЛЯЕВА
Priority to EA201201219A priority Critical patent/EA020389B1/en
Publication of EA201201219A1 publication Critical patent/EA201201219A1/en
Publication of EA020389B1 publication Critical patent/EA020389B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины, а именно офтальмологии. Задачей настоящего изобретения является создание эффективного фармацевтического состава, обладающего метаболическим, противокатарактным, ретинопротекторным действием за счет того, что фармацевтический состав содержит таурин и дополнительно содержит минеральные вещества, а также изотопыN. При реализации заявленных фармацевтических составов на практике будет обеспечено увеличение лечебного эффекта и скорости наступления лечебного эффекта без увеличения концентрации таурина, а также повышение стабильности фармацевтического состава с таурином в течение срока годности.The invention relates to the field of medicine, namely, ophthalmology. The present invention is the creation of an effective pharmaceutical composition with metabolic, anti-cataract, retinoprotective effect due to the fact that the pharmaceutical composition contains taurine and additionally contains minerals and isotopesN. When implementing the claimed pharmaceutical formulations in practice, there will be an increase in the therapeutic effect and speed of the onset of the therapeutic effect without an increase in the concentration of taurine, as well as an increase in the stability of the pharmaceutical composition with taurine during the shelf life.

EA201201219A 2012-10-01 2012-10-01 Pharmaceutical composition comprising sodium, iron, zinc and having a metabolic, anti-cataract, retina-protecting effect (variants) EA020389B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201201219A EA020389B1 (en) 2012-10-01 2012-10-01 Pharmaceutical composition comprising sodium, iron, zinc and having a metabolic, anti-cataract, retina-protecting effect (variants)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201201219A EA020389B1 (en) 2012-10-01 2012-10-01 Pharmaceutical composition comprising sodium, iron, zinc and having a metabolic, anti-cataract, retina-protecting effect (variants)

Publications (2)

Publication Number Publication Date
EA201201219A1 true EA201201219A1 (en) 2014-04-30
EA020389B1 EA020389B1 (en) 2014-10-30

Family

ID=50516412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201219A EA020389B1 (en) 2012-10-01 2012-10-01 Pharmaceutical composition comprising sodium, iron, zinc and having a metabolic, anti-cataract, retina-protecting effect (variants)

Country Status (1)

Country Link
EA (1) EA020389B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294206B1 (en) * 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
PA8591801A1 (en) * 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
RU2414218C1 (en) * 2009-12-11 2011-03-20 Закрытое акционерное общество "Институт фармацевтических технологий" Eye drops for treatment of dystrophic diseases and traumas of eyes

Also Published As

Publication number Publication date
EA020389B1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EA201800199A1 (en) APPLICATION OF AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF METABOLIC DISORDERS, INCREASE ENERGY CONSUMPTION AND WEIGHT REDUCTION, COMPOSITIONS, MEDICINE
EA201590667A1 (en) ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
EA201491500A1 (en) FIBROZA TREATMENT METHODS
EA201690005A1 (en) COMPOSITION WITH MODIFIED EXTRUSION KINETICS
EA201490045A1 (en) DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA
EA201200858A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201219A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201213A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201217A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201220A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201216A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201215A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201212A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201214A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201201218A1 (en) PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS)
EA201300370A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201300373A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201300392A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201300393A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201200469A1 (en) SOLID MEDICINE FORM WITH A FUNNY RELIEF, LOCAL ENVIRONMENT AND ANTI-INFLAMMATORY ACTION (OPTIONS)
EA201300371A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201300378A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)
EA201300394A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU